0RA9
vs
D
DAX Index
0RA9
In den letzten 12 Monate hat 0RA9 deutlich besser abgeschnitten als DAX Index, und erzielte eine Rendite von +1 297% gegenüber DAX Index +4% Anstieg.
Aktienperformance
0RA9 vs DAX Index
Performance-Unterschied
0RA9 vs DAX Index
Performance nach Jahr
0RA9 vs DAX Index
Vergleichen Sie die Rendite der Aktie mit ihrem Benchmark-Index und Wettbewerbern. Erhalten Sie Einblicke in die relative Performance im Zeitverlauf.
Abivax SA
Kurzüberblick
Abivax is a biotechnology company that develops drug candidates for inflammatory and immune-driven diseases. Its main work is research and clinical testing, especially for conditions like ulcerative colitis, where it is trying to turn its lead molecule into a prescription medicine. It is not a broad drug seller; it is a drug developer that owns and advances its own clinical programs. Because it does not yet have a large marketed drug portfolio, Abivax makes money mainly through financing its research and, if a program succeeds, through future drug sales or licensing deals. Its eventual customers would be patients, doctors, hospitals, and pharmacies that use the medicines it develops. In the value chain, it sits at the high-risk discovery and clinical-development stage, before large-scale commercial manufacturing and distribution. What makes Abivax different is that its business depends on one or a few scientific programs rather than a wide product lineup. That means the company’s value comes from its patents, trial data, and regulatory progress, not from selling many different products today. For investors, it is best understood as a focused biotech research company with the goal of turning a specific drug candidate into an approved treatment.
